Open AccessProtective effects of orally administered, Klebsiella‐containing bacterial lysates in mice
Author(s) -
Kuenen Janneke D.M.,
Dijke Etienne E.M.,
Hol Cees,
Bootsma Hester J.,
Verhoef Jan,
Dijk Hans
Publication year - 1994
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.1994.tb00427.x
Subject(s) - klebsiella , klebsiella pneumonia , klebsiella pneumoniae , microbiology and biotechnology , peritonitis , biology , sepsis , enterobacteriaceae , antibody , pneumonia , immunology , pharmacology , medicine , escherichia coli , bacteria , staphylococcus aureus , biochemistry , genetics , gene
The efficacy, as oral vaccines, of hepta‐ and mono‐valent, Klebsiella‐containing bacterial lysates and a number of control preparations was tested in mice. The preparations were administered during two periods of four days each, interrupted by an interval of 3 days. Fourteen days after the first dose, the animals were challenged either intraperitoneally (i.p.; peritonitis/sepsis model) or intranasally (i.n.; pneumonia model). Animals treated with low doses of Klebsiella lysate, in the form of either a 7‐valent lysate or a Klebsiella monolysate, showed enhanced survival in both the peritonitis/sepsis and the pneumonia models. Hexa‐ and tetra‐valent preparations without Klebsiella were not protective in the models tested. Furthermore, it was found that the protection is accompanied by priming for Klebsiella‐specific IgG responsiveness (probably at the T cell level) and by significant IgA anti‐Klebsiella serum antibody levels in about one third of the animals. The oral efficacy of Klebsiella‐containing lysates suggests the presence of an adjacent component that directs Klebsiella antigen(s) to follow a selective intestinal pathway which renders them immunogenic. The identity of this component is under investigation.